Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
| Autor: | George P. Chrousos, Theodora Kounadi, Nikos Voulgaris, George Piaditis, Labrini Papanastasiou, Athina Markou, Stelios Fountoulakis |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Hyperkalemia Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Blood Pressure 030204 cardiovascular system & hematology Plasma renin activity Urine sodium 03 medical and health sciences 0302 clinical medicine Primary aldosteronism Mineralocorticoid receptor Internal medicine Hyperaldosteronism Medicine Humans Salt intake Sodium Chloride Dietary Aged Mineralocorticoid Receptor Antagonists business.industry Sodium General Medicine Middle Aged medicine.disease Blood pressure Endocrinology Kaliuresis Potassium Female medicine.symptom business Follow-Up Studies |
| Zdroj: | Hormones (Athens, Greece). 19(2) |
| ISSN: | 2520-8721 |
| Popis: | Mild hyperkalemia is a common side effect of mineralocorticoid receptor antagonist (MRA) treatment of patients with primary aldosteronism (PA), which can be worsened by instructions to minimize salt intake. Our objective was to evaluate the effect of salt consumption on serum potassium levels and mean, mean minimal, and mean maximal systolic and diastolic blood pressure (BP) in MRA-treated hyperkalemic PA patients under relative salt restriction. Seventeen consecutive mildly hyperkalemic MRA-treated PA patients aged 66.3 ± 8.37 years were recruited. Body mass index (BMI) and BP were assessed, and serum and 24-h urinary sodium and potassium levels, plasma renin, and serum aldosterone were measured, while patients followed a relatively salt-restricted diet, after 1 month of controlled salt supplementation (usual salt-restricted diet plus 4 g salt/day) and after 6 months on instructions for free dietary salt consumption. Baseline salt consumption was additionally evaluated in two more patient groups (normotensive subjects and normokalemic MRA-treated PA patients). One month of controlled salt supplementation (24-h urine sodium (median, min, max): 195.2 (120.30–275.20) vs 110.13 (34.30–139.20) mEq/day, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink